Literature DB >> 12209731

Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.

Antiopi Varelias1, Simon A Koblar, Prudence A Cowled, Christopher D Carter, Mark Clayer.   

Abstract

BACKGROUND: The molecular mechanisms underlying malignancy of osteosarcoma are unknown. It has been reported that eph receptor protein tyrosine kinases and their ligands, ephrins, are associated with increased tumorigenicity in patients with breast carcinoma and melanoma. The expression and role of eph/ephrins in human osteosarcoma has not yet been characterized.
METHODS: Ephrin-A1, ephrin-A3, ephrin-A4, ephrin-A5, ephrin-B1, ephrin-B2, and ephrin-B3 mRNA expression was examined by reverse transcription polymerase chain reaction analysis in nine specimens of human osteosarcoma tissue and five human osteosarcoma cell lines. Ephrin-B1 protein expression was detected immunohistochemically in human osteosarcoma tissue. Clinicopathologic correlation was made between the osteosarcoma specimens and their ephrin expression profiles.
RESULTS: Normal bone specimens, osteosarcoma tissue specimens, and osteosarcoma cell lines expressed a distinct mRNA profile of ephrin-A1, ephrin-A4, and ephrin-B2. A second mRNA profile that included ephrin-A3, ephrin-A5, and ephrin-B1 was expressed by a subset of tumors. The expression of ephrin-B1 was correlated with a poorer clinical prognosis. Ephrin-B1 protein was expressed by osteosarcoma cells and blood vessels.
CONCLUSIONS: The results of this study suggest that ephrin-B1 expressed by osteosarcoma may be a poor prognostic marker through increased tumorigenicity. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10749

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209731     DOI: 10.1002/cncr.10749

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

2.  Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.

Authors:  Naohiko Koshikawa; Daisuke Hoshino; Hiroaki Taniguchi; Tomoko Minegishi; Taizo Tomari; Sung-Ouk Nam; Mikiko Aoki; Takayuki Sueta; Takashi Nakagawa; Shingo Miyamoto; Kazuki Nabeshima; Alissa M Weaver; Motoharu Seiki
Journal:  Cancer Res       Date:  2015-06-30       Impact factor: 12.701

3.  Ephrin-B1 reverse signaling controls a posttranscriptional feedback mechanism via miR-124.

Authors:  Dina N Arvanitis; Thomas Jungas; Annie Behar; Alice Davy
Journal:  Mol Cell Biol       Date:  2010-03-22       Impact factor: 4.272

4.  EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

Authors:  Fateme Haghiralsadat; Ghasem Amoabediny; Samira Naderinezhad; Kamran Nazmi; Jantine Posthuma De Boer; Behrouz Zandieh-Doulabi; Tymour Forouzanfar; Marco N Helder
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

Review 5.  Membrane-mediated regulation of vascular identity.

Authors:  Takuya Hashimoto; Masayuki Tsuneki; Trenton R Foster; Jeans M Santana; Hualong Bai; Mo Wang; Haidi Hu; Jesse J Hanisch; Alan Dardik
Journal:  Birth Defects Res C Embryo Today       Date:  2016-03-17

6.  Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma.

Authors:  Masamitsu Tanaka; Reiko Kamata; Misato Takigahira; Kazuyoshi Yanagihara; Ryuichi Sakai
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 7.  Diagnostic and prognostic sarcoma signatures.

Authors:  Elai Davicioni; Daniel H Wai; Michael J Anderson
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  EphrinB1 interacts with CNK1 and promotes cell migration through c-Jun N-terminal kinase (JNK) activation.

Authors:  Hee Jun Cho; Yoo-Seok Hwang; Kathleen Mood; Yon Ju Ji; Junghwa Lim; Deborah K Morrison; Ira O Daar
Journal:  J Biol Chem       Date:  2014-05-13       Impact factor: 5.157

9.  Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.

Authors:  Ben Davidson; Vera Maria Abeler; Ellen Hellesylt; Arild Holth; Ie-Ming Shih; Tone Skeie-Jensen; Li Chen; Yanqin Yang; Tian-Li Wang
Journal:  Gynecol Oncol       Date:  2012-11-21       Impact factor: 5.482

10.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.